Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

0.99USD
21 Feb 2017
Change (% chg)

-- (--)
Prev Close
$0.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
112,449
52-wk High
$2.00
52-wk Low
$0.97

DRRX.OQ

Chart for DRRX.OQ

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $137.20
Shares Outstanding(Mil.): 138.58
Dividend: --
Yield (%): --

Financials

  DRRX.OQ Industry Sector
P/E (TTM): -- 46.79 29.35
EPS (TTM): -0.24 -- --
ROI: -80.85 -3.72 12.97
ROE: -209.20 4.91 14.11

BRIEF-Durect says working with clinical advisors to design phase 2 studies on dur-928 development program

* Durect corporation announces update on dur-928 development program

Jan 30 2017

BRIEF-Durect Corp announces update on DUR-928 development program

* Durect-Report data from cohort 1 of first patient study with DUR-928,single dose provided signals of DUR-928 activity in cirrhotic,non-cirrhotic NASH patients

Oct 31 2016

BRIEF-Durect Corp announces Q3 financial results and update of programs

* Q3 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S

Oct 31 2016

More From Around the Web

Earnings vs. Estimates